摩根中国生物医药混合(QDII)C(019573)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
23,053,522.74 |
168,281,212.36 |
131,967,400.52 |
-77,034,585.41 |
| 利息合计 |
68,397.14 |
86,413.19 |
19,893.29 |
203,447.46 |
| 其中:存款利息收入 |
68,397.14 |
86,413.19 |
19,893.29 |
203,447.46 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
24,864,422.87 |
121,726,995.33 |
21,429,277.68 |
-109,679,838.89 |
| 其中:股票投资收益 |
22,508,854.98 |
119,598,938.67 |
19,712,203.58 |
-113,810,856.75 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
2,355,567.89 |
2,128,056.66 |
1,717,074.10 |
4,131,017.86 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-905,226.47 |
47,142,547.59 |
110,841,277.95 |
31,020,938.89 |
| 其他收入 |
190,469.30 |
618,732.96 |
150,564.73 |
101,339.70 |
| 费用 |
3,668,807.41 |
7,866,180.25 |
3,595,566.13 |
8,073,387.79 |
| 管理人报酬 |
3,016,371.70 |
6,528,423.89 |
3,001,543.78 |
6,766,031.88 |
| 基金托管费 |
502,728.57 |
1,088,070.66 |
500,257.28 |
1,127,671.93 |
| 销售服务费 |
62,213.99 |
72,305.28 |
7,255.10 |
5,505.28 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
87,493.15 |
177,380.42 |
86,509.97 |
174,178.70 |
| 利润总额 |
19,384,715.33 |
160,415,032.11 |
128,371,834.39 |
-85,107,973.20 |